EUVIMEDEUVIMED entdecken
Crossref

Clinical significance of circulating biomarkers of immune-checkpoint molecules with atezolizumab plus bevacizumab therapy in unresectable hepatocellular carcinoma

Makoto Chuma, Haruki Uojima, Hidenori Toyoda, Atsushi Hiraoka, Yoshitake Arase, Masanori Atsukawa, Norio Itokawa, Tomomi Okubo, Toshifumi Tada, Kazushi Numata, Manabu Morimoto, Makoto Sugimori und 13 weitere

Hepatology International · 2024-10 · 18 (5) · 1472-1485

DOI: 10.1007/s12072-024-10680-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hepatology International, online erschienen am 04.07.2024. Verfasst von Makoto Chuma und 24 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterological Center, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama, Kanagawa, Japan. chuma@yokohama-cu.ac.jp. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Antibodies, Monoclonal, Humanized, Bevacizumab. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The aims of this study were to identify clinically significant biomarkers of a response to atezolizumab plus bevacizumab (ATZ + BV) therapy and to develop target strategies against unresectable hepatocellular carcinoma (u-HCC). METHOD: We first investigated the potential of circulating tumor DNA (ctDNA) to serve as a biomarker for predicting the therapeutic outcome in 24 u-HCC patients treated with ATZ + BV therapy. Next, we analyzed levels of immune-related cytokines in blood samples from 134 u-HCC patients who received ATZ + BV. For this, serum immune-related molecules or cancer-immune cycle-related molecules that have been reported in HCC patient sera, namely CD274, LAG-3, CCL2, 4, 5, CXCL1, 9, 10, 12, 13, CX3CL1, CCR5, IFNγ and IL-6, 8 were measured using enzyme-linked immunosorbent assay. RESULTS: More than 1% of variant read frequency (VRF) mutations were found in TP53, APC, PIK3CA and VHL, although with no correlation with treatment response. Among the 15 cytokines evaluated, CXCL9 and LAG-3 levels were significantly different between patients with objective response (OR), stable disease (SD), and progressive disease (PD) following ATZ + BV treatment. Receiver-operating characteristic curve analyses of CXCL9 (cut-off value: 419.1 pg/ml) and LAG-3 (cut-off value: 3736.3 pg/ml) indicated areas of 0.779 and 0.697, respectively, for differentiating PD from non-PD and OR from non-OR. In multivariate analysis of progression-free survival (PFS) and overall survival (OS), high serum CXCL9 (hazard ratio (HR) and 95% confidence interval (CI): 0.412 (0.251-0.677) (p = 0.0005) for PFS and 0.252 (0.125-0.508) (p = 0.0001) for OS), and low serum LAG-3 (HR and 95% CI 0.419 (0.249-0.705) (p = 0.0011) for PFS and 0.294 (0.140-0.617) (p = 0.0012) for OS) were independent positive predictive factors. CONCLUSION: Although, as far as we examined, no ctDNA mutations in blood were found to be related to ATZ + BV treatment efficacy, serum CXCL9 and LAG-3 levels, which are related to the cancer-immune cycle, were associated with treatment efficacy and could be predictive markers of the efficacy of ATZ + BV treatment in HCC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver NeoplasmsCarcinoma, HepatocellularAntibodies, Monoclonal, HumanizedBevacizumabBiomarkers, TumorCirculating Tumor DNAAntineoplastic Combined Chemotherapy ProtocolsLymphocyte Activation Gene 3 ProteinHumansMaleFemaleMiddle AgedAgedChemokine CXCL9Antigens, CDAdultImmune Checkpoint InhibitorsCytokinesTreatment OutcomeB7-H1 AntigenClinical Relevance

Stichwörter der Autor:innen

Atezolizumab plus bevacizumabCXCL9Hepatocellular carcinomaImmune-checkpoint inhibitorLAG-3

Substanzen

Antibodies, Monoclonal, HumanizedatezolizumabBevacizumabBiomarkers, TumorCirculating Tumor DNALymphocyte Activation Gene 3 ProteinLag3 protein, humanCXCL9 protein, humanChemokine CXCL9Antigens, CD

Autor:innen und Institutionen

  • Gastroenterological Center, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama, Kanagawa, Japan. chuma@yokohama-cu.ac.jp.
  • Department of Gastroenterology, Internal Medicine, Kitasato University School of Medicine, Sagamihara, Japan.
  • Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki, Japan.
  • Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
  • Division of Gastroenterology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan.
  • Division of Gastroenterology, Department of Internal Medicine, Nippon Medical School Hospital, Tokyo, Japan.

Zitieren

APA

Chuma, M., Uojima, H., Toyoda, H., Hiraoka, A., Arase, Y., Atsukawa, M., Itokawa, N., Okubo, T., Tada, T., Numata, K., Morimoto, M., Sugimori, M., Nozaki, A., Iwasaki, S., Yasuda, S., Koshiyama, Y., Mishima, Y., Tsuruya, K., Tokoro, C., …, & Maeda, S. (2024). Clinical significance of circulating biomarkers of immune-checkpoint molecules with atezolizumab plus bevacizumab therapy in unresectable hepatocellular carcinoma. Hepatology International, 18(5), 1472-1485. https://doi.org/10.1007/s12072-024-10680-8

Vancouver

Chuma M, Uojima H, Toyoda H, Hiraoka A, Arase Y, Atsukawa M, et al. Clinical significance of circulating biomarkers of immune-checkpoint molecules with atezolizumab plus bevacizumab therapy in unresectable hepatocellular carcinoma. Hepatology International. 2024;18(5):1472-1485. doi:10.1007/s12072-024-10680-8

BibTeX
@article{Chuma2024,
  author = {Chuma, Makoto and Uojima, Haruki and Toyoda, Hidenori and Hiraoka, Atsushi and Arase, Yoshitake and Atsukawa, Masanori and Itokawa, Norio and Okubo, Tomomi and Tada, Toshifumi and Numata, Kazushi and Morimoto, Manabu and Sugimori, Makoto and Nozaki, Akito and Iwasaki, Shuichiro and Yasuda, Satoshi and Koshiyama, Yuichi and Mishima, Yusuke and Tsuruya, Kota and Tokoro, Chikako and Miura, Yuki and Hidaka, Hisashi and Kumada, Takashi and Kusano, Chika and Kagawa, Tatehiro and Maeda, Shin},
  title = {Clinical significance of circulating biomarkers of immune-checkpoint molecules with atezolizumab plus bevacizumab therapy in unresectable hepatocellular carcinoma},
  journal = {Hepatology International},
  year = {2024},
  volume = {18},
  number = {5},
  pages = {1472--1485},
  doi = {10.1007/s12072-024-10680-8}
}
Kostenlos starten →